Spero Therapeutics, Inc.SPRONASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank60
3Y CAGR+9.0%
5Y CAGR-2.3%
Year-over-Year Change
Research and development spending
3Y CAGR
+9.0%/yr
vs +8.9%/yr prior
5Y CAGR
-2.3%/yr
Recent acceleration
Acceleration
+0.2pp
Accelerating
Percentile
P60
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $61.71M | -36.2% |
| 2024 | $96.76M | +88.1% |
| 2023 | $51.44M | +8.1% |
| 2022 | $47.59M | -26.2% |
| 2021 | $64.53M | -7.0% |
| 2020 | $69.40M | +2.3% |
| 2019 | $67.88M | +100.3% |
| 2018 | $33.88M | +3.1% |
| 2017 | $32.87M | +24.8% |
| 2016 | $26.33M | - |